Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
BACKGROUND
JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3 and Src family (Lyn, Fyn, Yes) at low nanomolar concentrations. This phase I, accelerated titration study assessed maximum tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327.


METHODS
Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts ranging from 100 to 2100 mg. Pharmacodynamic effects were assessed in paired skin biopsies and blood.


RESULTS
JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhoea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue. At 2100 mg, two episodes of dose-limiting toxicity were observed, consisting of grade 3 anorexia and a combination of grade 3 anorexia and fatigue, respectively. Pharmacokinetics were dose proportional up to 1500 mg in which plasma levels were obtained showing anti-tumour activity in xenograft mouse models. Pharmacodynamic analysis did not show a substantial effect on expression of Ki-67, p27(kip1), phosphorylated mitogen-activated protein kinase, phosphorylated Akt and EGFR, and serum levels of sVEGFR-2, VEGF-C and VEGF-D remained unchanged. Stable disease was noted in six patients (32%).


CONCLUSIONS
JNJ-26483327 is well tolerated and shows a predictable pharmacokinetic profile; the recommended dose for further studies is 1500 mg BID.
Konings
I R H M
IR
Department of Medical Oncology, Erasmus University Medical Center, Room HE-118, P.O. Box 2040, Rotterdam 3000 CA, The Netherlands. i.konings@erasmusmc.nl
de Jonge
M J A
MJ
Burger
H
H
van der Gaast
A
A
van Beijsterveldt
L E C
LE
Winkler
H
H
Verweij
J
J
Yuan
Z
Z
Hellemans
P
P
Eskens
F A L M
FA
D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D047028:Macrocyclic Compounds / Q000494:pharmacology*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; C553025:JNJ-26483327; D047028:Macrocyclic Compounds; D047428:Protein Kinase Inhibitors
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Nat Rev Cancer. 2006 Oct;6(10):803-12
16990857
Cancer Cell. 2002 Mar;1(2):117-23
12086869
J Clin Oncol. 2006 Jan 1;24(1):4-5
16314613
Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20
18777950
Target Oncol. 2009 Apr;4(2):107-19
19452131
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4589-92
17671146
Gut. 1996 Aug;39(2):262-6
8977341
J Clin Oncol. 2009 Jul 10;27(20):3312-8
19451442
Nature. 2001 May 17;411(6835):355-65
11357143
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
Crit Rev Oncol Hematol. 2000 May;34(2):83-8
10799834
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Nat Rev Clin Oncol. 2009 Jun;6(6):327-38
19483739
Nat Clin Pract Oncol. 2008 May;5(5):268-78
18349858
N Engl J Med. 2002 Aug 15;347(7):472-80
12181401
Curr Drug Metab. 2009 Jun;10(5):470-81
19689244
Mod Pathol. 1998 Feb;11(2):155-68
9504686
J Clin Oncol. 2009 Aug 1;27(22):3584-90
19487381